Agammaglobulinemia: causative mutations and their implications for novel therapies
Authors:
- Janne J TurunenJTJanne J Turunen
- Olof GissbergOGOlof Gissberg
- Burcu BestasBBBurcu Bestas
- K Emelie M BlombergKBK Emelie M Blomberg
- Ci Edvard SmithCSCi Edvard Smith
- 1 December 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 9 (12) , 1205-1221
Abstract
Agammaglobulinemias are primary (inherited) immunodeficiencies characterized by the lack of functional B-cells and antibodies, and are caused by mutations in genes encoding components of the pre-B-cell or B-cell receptor, or their signaling pathways. The known genetic defects do not account for all agammaglobulinemic patients, suggesting that novel mutations underlying the disease remain to be found. While efficient, the current life-maintaining therapy with immunoglobulins and antibiotics is non-curative, prompting research into alternative treatment strategies that aim at rescuing the expression of the affected protein, thus giving rise to functional B-cells. These include gene therapy, which could be used to correct the defective gene or replace it with a functional copy. For a number of genetic defects, another alternative is to modulate the splicing of the affected transcripts. While these technologies are not yet ready for clinical trials in agammaglobulinemia, advances in genomic targeting are likely to make this option viable in the near future.Keywords
This publication has 97 references indexed in Scilit:
- Splicing therapy for neuromuscular diseaseMolecular and Cellular Neuroscience, 2013
- Genomic Editing of the HIV-1 Coreceptor CCR5 in Adult Hematopoietic Stem and Progenitor Cells Using Zinc Finger NucleasesMolecular Therapy, 2013
- Fyn Kinase Is Required for Optimal Humoral ResponsesPLOS ONE, 2013
- Alpharetroviral Self-inactivating Vectors: Long-term Transgene Expression in Murine Hematopoietic Cells and Low GenotoxicityMolecular Therapy, 2012
- Genetic engineering of human pluripotent cells using TALE nucleasesNature Biotechnology, 2011
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- Development of B-lineage Predominant Lentiviral Vectors for Use in Genetic Therapies for B Cell DisordersMolecular Therapy, 2011
- Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiationNature Immunology, 2008
- Gross Deletions Involving IGHM, BTK, or Artemis: A Model for Genomic Lesions Mediated by Transposable ElementsThe American Journal of Human Genetics, 2008
- Defective B cell development and function in Btk-deficient miceImmunity, 1995